Sep 06, 2023 / 07:30PM GMT
David Neil Lebowitz - Citigroup Inc., Research Division - Research Analyst
Hello. Thank you all for coming again to the 18th Annual Citi Biopharma Conference. Happy to have on stage with me from BioMarin, certainly been an exciting last few years, biggest commercial launch in history with Voxzogo the upcoming or ongoing launch as of just recently, launch of Roctavian for hemophilia A and of course, a large portfolio of ultra-rare diseases.
Questions and Answers:
David Neil Lebowitz - Citigroup Inc., Research Division - Research AnalystCould you start by walking us through BioMarin, its history and really these transformative recent years?
Brian R. Mueller - BioMarin Pharmaceutical Inc. - CFO & Executive VP
Great. Thanks. Thanks, David. Thanks for having us. Thanks for participating, everyone. And yes, BioMarin has been on a steady growth journey throughout our 25-year history. We grew up around mostly ultra-orphan therapies. These are ultra-rare metabolic disorders, very small patient populations, very